Clinical trials: Hypertriglyceridemia
- Condition Hypertriglyceridemia
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Disbiosis, Obesity
Limosilactobacillus Fermentum CRL 1446 - CONICET CASASCO
This research study aims to determine if a probiotic called Limosilactobacillus fermentum CRL 1446 can improve the health of people at risk for cardiovascular disease.
- Conditions
- Disbiosis, Obesity, Overweight (BMI > 25), Hypertension (Without Type 2 Diabetes Mellitus)
- Trial name
- NCT07530575
- Testing
- Limosilactobacillus fermentum 1446 CRL CONICET 2.20E+9 CFU
- Where
- 2 sites in Argentina
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- PINER Pastor Manfredi Winery
Healthy Subjects, Hyperlipidemia, Hypertriglyceridemia
First-in-Human Study of ISH0688: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics
ISH0688 is a human IgG1 Fc-FGF21 fusion protein. The objectives of the planned clinical investigation will be to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single- and…
- Trial name
- NCT07505043
- Testing
- ISH0688 for injection
- Where
- China
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
Hypertriglyceridemia
Single-ascending Dose Study of Kylo-12 in Healthy Subjects
This is a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study in healthy volunteers. Kylo-12 will be evaluated in approximately 50 subjects to assess safety, tolerability, pharmacokinetics…
- Trial name
- NCT06783881
- Testing
- Kylo-12
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Kylonova (Xiamen) Biopharma co., LTD.
Hypertriglyceridemia, Familial Chylomicronemia Syndrome
Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of single doses of RN0361 in Adult healthy subjects and Adult Hypertriglyceridemic Subjects.
- Trial name
- NCT06471543
- Testing
- RN0361
- Where
- 10 sites in United States, Australia
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Ikaria Bioscience Pty Ltd
Dyslipidemias, Familial Hypercholesterolemia
Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetcs and pharmacodynamics of single- and multiple doses of ARO-ANG3 in healthy adult volunteers and in dyslipidemic patients including familial…
- Conditions
- Dyslipidemias, Familial Hypercholesterolemia, Hypertriglyceridemia
- Trial name
- NCT03747224
- Testing
- ARO-ANG3, sterile normal saline (0.9% NaCl)
- Where
- 6 sites in Australia, New Zealand
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Hypertriglyceridemia, Familial Chylomicronemia
Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single- and multiple doses of ARO-APOC3 in healthy adult volunteers and in patients with severe hypertriglyceridemia and…
- Trial name
- NCT03783377
- Testing
- ARO-APOC3, sterile normal saline (0.9% NaCl)
- Where
- 10 sites in Australia, Canada and 1 more
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Dyslipidemias, Familial Hypercholesterolemia
A VSA003 Phase 1 Study in Chinese Adult Healthy Volunteers
This is a randomized, double blinded, phase 1 study. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single dose of VSA003 in healthy adult volunteerst
- Conditions
- Dyslipidemias, Familial Hypercholesterolemia, Hypertriglyceridemia
- Trial name
- NCT05851066
- Testing
- VSA003, 0.9% NaCl
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Visirna Therapeutics HK Limited
Hypertriglyceridemia
A Study of LY3875383 in Healthy Participants and Participants With Hypertriglyceridemia
The main purpose of this study is to determine the tolerability and side effects related to LY3875383 given as a single injection under the skin to healthy participants and participants with elevated triglyceride (TG) levels.The…
- Trial name
- NCT05609825
- Testing
- LY3875383
- Where
- Singapore
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Hypertriglyceridemia
A Phase 1, First Time in Humans Study of NST-1024
A first time in man study of NST-1024
- Trial name
- NCT04630366
- Testing
- NST-1024
- Where
- United Kingdom
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- NorthSea Therapeutics B.V.
Diabetes Mellitus, Non-Insulin-Dependent, Hypertriglyceridemia
PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA
The primary objective of the study is to contrast the pharmacokinetic profiles of metformin and EPA delivered separately as co-administered products (metformin hydrochloride or Glucophage and icosapent ethyl or Vascepa) and…
- Trial name
- NCT02113163
- Testing
- Metformin Eicosapentaenoate, Metformin HCl and Vascepa
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Thetis Pharmaceuticals LLC
Hypertriglyceridemia
Effect of Candida Rugosa Lipase on Serum Triglyceride Lowering
The primary objective of this study was to evaluate the safety and tolerability of 3 doses of fungal lipase in the treatment of adults with mildly elevated serum triglycerides.
- Trial name
- NCT05295134
- Testing
- Candida cylindracea lipase (225,000 FIP lipase units per day), Candida cylindracea lipase (450,000 FIP lipase units per day), Candida cylindracea lipase (675,000 FIP lipase units per day)
- Where
- Ireland
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- BIO-CAT, Inc.
Dyslipidemia Associated With Type II Diabetes Mellitus
Efficacy and Safety of the Fixed-dose Combination Atorvastatin/Fenofibrate vs Atorvastatin in Patients With T2D and DLP.
Phase IIIb, randomized, longitudinal, prospective, multicenter study to evaluate the efficacy and safety of the fixed-dose combination atorvastatin / fenofibrate versus atorvastatin on the lipid profile of patients with type 2…
- Trial name
- NCT04882293
- Testing
- Atorvastatin 20 mg / Fenofibrate 160 mg in fixed dose, Atorvastatin (Lipitor ®)
- Where
- Mexico
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Elevated Triglycerides
A Study to Evaluate the Effect of GFA-918 on Serum Triglyceride Levels in Individuals With Elevated Serum Triglyceride
In this study, a lipase -sourced from a nonpyrogenic yeast, Candida rugosa, will be investigated to establish optimal TG levels in adults in a 12-week supplementation period.
- Trial name
- NCT04754373
- Testing
- GFA-918
- Where
- 2 sites in Canada
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- BIO-CAT Microbials, LLC
Triglycerides High
Clinical Study to Evaluate the Blood Triglyceride Decreasing Effect and Safety of Korean Post-Fermented Tea Extracts
This study was conducted to investigate the effects of daily supplementation of Korean Post-Fermented Tea(Heukcha) Extracts on improvement of Blood Triglyceride Level.
- Trial name
- NCT04850352
- Testing
- Heukcha Extracts
- Where
- 3 sites in South Korea
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Amorepacific Corporation
Hypertriglyceridemia, Familial Hypercholesterolemia
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Participants With Familial Hypercholesterolemia
The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS ANGPTL3-LRx (ISIS 703802) given to healthy volunteer subjects with elevated triglycerides and subjects with familial…
- Trial name
- NCT02709850
- Testing
- IONIS ANGPTL3-LRx
- Where
- Canada
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Ionis Pharmaceuticals, Inc.
Prediabetes, Type 2 Diabetes
Effect of Totum-63, Active Ingredient of Valedia, on Glucose and Lipid Homeostasis on Subjects With Prediabetes
Given the data on the active ingredients of Totum-63, this research aims to evaluate the effect of its chronic consumption (24 weeks) on glucose and lipid homeostasis and especially on fasting plasma glucose in volunteers with…
- Conditions
- Prediabetes, Type 2 Diabetes, Hypertriglyceridemia, Obesity
- Trial name
- TOTUM-63 TWO (NCT02868177)
- Testing
- Totum-63
- Where
- 6 sites in France, Ireland and 2 more
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Valbiotis
Hypercholesterolemia, Hypertriglyceridemia
Effects of Two Herbal Dietary Supplements on Lipid Metabolism in Moderate Hypercholesterolemia and Hypertriglyceridemia
This study is designed as a pilot study in order to estimate the effect of VAL070-A and VAL070-B products and their variability on LDL cholesterol and lipid metabolism since these data are still unknown for these products and in…
- Trial name
- Lipiback (NCT02989753)
- Testing
- VAL070-A, VAL070-B
- Where
- France
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Valbiotis
Elevated Triglycerides (TG)
Safety, Tolerability, PK, and Pharmacodynamics(PD) of IONIS APOCIII-LRx in Healthy Volunteers With Elevated Triglycerides
The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS APOC-III-LRx given to healthy volunteer subjects.
- Trial name
- NCT02900027
- Testing
- APOC-III-L-Rx
- Where
- Canada
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Ionis Pharmaceuticals, Inc.
Hyperlipidemia, Hypertriglyceridemia
Phase I Drug-drug Interaction of Omega-3 and Atorvastatin
This study evaluates the safety and pharmacokinetic drug-drug interactions of omega-3 and atorvastatin in healthy male volunteers.
- Trial name
- NCT03438955
- Testing
- Omacor, Pritor, Omacor + Pritor
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- DongKoo Bio & Pharma
Cardiovascular Disease
An Open-label Single Dose Randomized, Parallel Group Study Followed by Single-blind Repeat Dosing, to Compare the Relative Bioavailability of GSK2212836.
Sixteen healthy subjects will be randomized to each of the 3 parallel treatment groups. Eligible subjects will check in to the clinical unit on Day -2 and have 24-hr pharmacokinetic collections on Day -1 and on Day 1.
- Trial name
- NCT00996268
- Testing
- GSK2212836
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline